Skip to content

Released Feb 26, 2026, after the close

10-K filed Feb 26, 2026, 57 days after period end · 0001628280-26-012352

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$62.14Mderived+8.1% vs Q4 2024+18.8% vs Q3 2025
Net Income-$44.08MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$32,885,000−2.3%
Operating Incomederived-$5,593,000N/M
Operating Cash Flowderived-$771,000N/M
Free Cash Flowderived-$1,772,000N/M
Margins · derived
Gross margin52.9%−5.6 pt vs Q4 2024
Operating margin-9.0%−14.2 pt vs Q4 2024
Net margin-70.9%−87.7 pt vs Q4 2024

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Revenue$62.14M$57.48M$58.23M$48.34M
Net Income-$44.08M$9.64M$5.50M$3.72M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR